Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin
1999
How DNA Repair Affects Cancer Treatment
publication
Author Information
Author(s): Bruno Cenni, Heung-Ki Kim, George J. Bubley, Stefan Aebi, David Fink, Bruce A. Teicher, Stephen B. Howell, Richard D. Christen
Primary Institution: University of California San Diego
Hypothesis
Does the loss of DNA mismatch repair (MMR) affect the reactivation of a reporter plasmid damaged by cisplatin?
Conclusion
Loss of a functional MMR system facilitates the reactivation of a cisplatin-damaged reporter gene.
Supporting Evidence
- MMR deficiency did not change the extent of platinum accumulation in cells.
- MMR-deficient cells generated twofold more luciferase activity from a cisplatin-damaged plasmid than MMR-proficient cells.
- The efficiency of reactivation of the damaged luciferase gene was reduced in MMR-proficient cells.
Takeaway
When cells can't fix DNA mistakes, they can recover better from damage caused by a cancer drug called cisplatin.
Methodology
The study compared MMR-proficient and -deficient cells in their ability to remove cisplatin adducts and reactivate a damaged plasmid.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website